Long-term safety of HSK39297 for PNH patients
Treatments studied
Part of Blood & lymphatic clinical trials.
This study is for people with paroxysmal nocturnal hemoglobinuria (PNH) who have already taken the experimental drug HSK39297. It checks the long-term safety of continuing the treatment and makes sure it is still helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already taken the study drug HSK39297 in a previous clinical trial and completed it.
- Your doctor must believe that the benefits of continuing HSK39297 outweigh any risks.
- You cannot have a genetic or acquired problem with your complement immune system.
- You cannot have had your spleen removed or received a bone marrow, stem cell, or organ transplant.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HS-10542, for people with PNH who are already on a C5 inhibitor like eculizumab or covalizumab but still have low hemoglobin or need transfusions. It aims to see if this additional treatment can improve blood counts and reduce transfusion needs.
This study is a follow-up for people who already finished the earlier phase 2 trial of the study drug LP-005 for PNH. The goal is to see if it's safe and effective for long-term treatment.
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This trial tests an investigational drug called NM8074 for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet been treated with complement inhibitors. The goal is to see if NM8074 can reduce red blood cell destruction and improve anemia, potentially reducing the need for blood transfusions.
This is a long-term registry study for people with a confirmed diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). It simply collects information over time to better understand the condition and how it's managed. There is no experimental treatment involved.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.